Optomed Plc: Interim Report, January – March 2023
Optomed Plc Stock Exchange Release 5 May 2023 at 9.00, Helsinki January – March 2023 · Revenue increased by 8.2 percent to EUR 3.5 (3.2) million. · Software segment revenue increased by 20.5 percent to EUR 2.6 (2.2) million driven by strong healthcare solution sales. · Devices segment revenue decreased by 16.5 percent to EUR 0.9 (1.1) million due to a slow quarter of the OEM and Chinese sales channels. · EBITDA amounted to EUR -0.5 (-0.9) million corresponding to -14.8 (-29.2) percent of revenue. · Outlook unchanged: Optomed expects its full year 2023